Myelodysplastic syndromes, version 2.2015

• Published in: Journal of the National Comprehensive Cancer Network Vol. 13; no. 3; p. 261
• Main Authors: Greenberg, Peter L, Stone, Richard M, Bejar, Rafael, Bennett, John M, Bloomfield, Clara D, Borate, Uma, De Castro, Carlos M, Deeg, H Joachim, DeZern, Amy E, Fathi, Amir T, Frankfurt, Olga, Gaensler, Karin, Garcia-Manero, Guillermo, Griffiths, Elizabeth A, Head, David, Klimek, Virginia, Komrokji, Rami, Kujawski, Lisa A, Maness, Lori J, O'Donnell, Margaret R, Pollyea, Daniel A, Scott, Bart, Shami, Paul J, Stein, Brady L, Westervelt, Peter, Wheeler, Benton, Shead, Dorothy A, Smith, Courtney
• Format: Journal Article
• Language: English
• Published: United States 01.03.2015
• Subjects: Cost-Benefit Analysis; Disease Management; Genetic Testing; Humans; Myelodysplastic Syndromes - diagnosis; Myelodysplastic Syndromes - genetics; Myelodysplastic Syndromes - therapy; Prognosis
• ISSN: 1540-1413
• DOI: 10.6004/jnccn.2015.0038

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care.